Hematide

Hematide is an an investigational synthetic peptide, substituted with polyethylene glycol (thus described as "PEGylated"). It is a novel erythropoietic agent, being an analog of erythropoietin, ["Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers" Blood, 15 September 2006, Vol. 108, No. 6, pp. 1830-1834." [http://bloodjournal.hematologylibrary.org/cgi/content/short/blood-2006-04-015818v1 abstract] ] and has been developed for medical use as a treatment for asthma, ["Hematide for the Treatment of Anemia: An Expert Interview With Iain C. Macdougall, BSc, MD, FRCP" [http://www.medscape.com/viewarticle/548672 Medscape Nephrology] ] now in stage 3 clinical trials. Whether it will be approved is not certain. ["Affymax wavers on forecast of Hematide approval" by Marley Seaman "Associated Press", July 2, 2008 [http://www.boston.com/business/healthcare/articles/2008/07/02/affymax_wavers_on_forecast_of_hematide_approval/ Boston.com] ]

References